Qlife entered into a final collaboration agreement with Hipro Biotechnology. The parties will from now on work diligently towards achieving market clearance for Egoo Health from the China FDA ? expected to take 12-18 months for 3 Egoo tests initially.

From the time of market clearance, the value of the collaboration on the Chinese market in the first full year is estimated to be 10-20% of Hipro unit sales which currently is approx. 25 million tests per year. Hence the value of the agreement is estimated to be sales in the range 100-200 MSEK (ratio 80/20 tests/devices).

After five years it is expected that the collaboration with Hipro will enable an extensive menu of at-home tests on the Egoo system generating sales in the range of 300-500 MSEK from the Chinese market.